Gapping up
News:
- BITF +9.3% (mines 411 BTC in September)
- HOLI +4.3% (announces formal sale process as part of review of strategic options)
- DFS +3.9% (disclosed Friday night that FDIC issued the previously disclosed consent order which addresses shortcomings in Discover Bank's compliance management system for consumer protection laws and related matters)
- TLRY +3.3% (closes its all-cash previously-announced acquisition of eight beer and beverage brands from Anheuser-Busch (BUD))
- VTRS +2.4% (announces agreements on remaining planned divestitures; Upon closing would achieve its original total target of a multiple above 12x on 2022 estimated adjusted EBITDA)
- APLS +1.9% (announces that the U.S. Food and Drug Administration has approved the EMPAVELI Injector)
- DXCM +1.8% (Solidifies Global Leadership in Continuous Glucose Monitoring With New Clinical Data Presented at EASD)
- CABA +1.8% (receives FDA Clearance of IND Application for Treatment of Systemic Sclerosis with CABA-201)
- BBVA +1.7% ( announces EUR1.0 bln share buyback)
- HUM +1.5% (2024 Medicare Advantage Health Plan Offerings)
- GNL +1.5% (declares dividend of $0.354 per share)
- LI +1.4% (Sep deliveries)
- XPEV +1.2% (Sep deliveries)
- RCKT +1.2% (receives FDA acceptance of Biologics License Application with Priority Review for RP-L201)
- DHR +1% (completes separation of Veralto Corporation)
Analyst comments:
- PODD +3.4% (upgraded to Buy from Hold at Jefferies)
- ZS +3.1% (upgraded to Overweight from Neutral at Piper Sandler)
- MAC +1.7% (upgraded to Neutral from Underweight at Piper Sandler)
- CLX +1.3% (upgraded to Buy from Neutral at DA Davidson)
- LGIH +1.3% (upgraded to Neutral from Sell at BTIG Research)
- FDX +0.8% (upgraded to Positive from Neutral at Susquehanna)